For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review

 
• By Ramsey Baghdadi

For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.

Global Marekt Price tag
Proposals for an International Pricing Index in Medicare Part B and for eliminating the safe harbor for drug rebates in Medicare Part D and Medicaid managed care are in the final stage of regulatory review. • Source: Shutterstock

More from Pricing Debate

More from Market Access